Stock Research for NVGN

NVGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

NVGN Stock Chart & Research Data

The NVGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NVGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


NVGN Due diligence Resources & Stock Charts

The NVGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View NVGN Detailed Price Forecast - CNN Money CNN View NVGN Detailed Summary - Google Finance
Yahoo View NVGN Detailed Summary - Yahoo! Finance Zacks View NVGN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View NVGN Trends & Analysis - Trade-Ideas Barrons View NVGN Major Holders - Barrons
NASDAQ View NVGN Call Transcripts - NASDAQ Seeking View NVGN Breaking News & Analysis - Seeking Alpha
Spotlight View NVGN Annual Report - CompanySpotlight.com OTC Report View NVGN OTC Short Report - OTCShortReport.com
TradeKing View NVGN Fundamentals - TradeKing Charts View NVGN SEC Filings - Bar Chart
WSJ View Historical Prices for NVGN - The WSJ Morningstar View Performance/Total Return for NVGN - Morningstar
MarketWatch View the Analyst Estimates for NVGN - MarketWatch CNBC View the Earnings History for NVGN - CNBC
StockMarketWatch View the NVGN Earnings - StockMarketWatch MacroAxis View NVGN Buy or Sell Recommendations - MacroAxis
Bullish View the NVGN Bullish Patterns - American Bulls Short Pains View NVGN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View NVGN Stock Mentions - StockTwits PennyStocks View NVGN Stock Mentions - PennyStockTweets
Twitter View NVGN Stock Mentions - Twitter Invest Hub View NVGN Investment Forum News - Investor Hub
Yahoo View NVGN Stock Mentions - Yahoo! Message Board Seeking Alpha View NVGN Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for NVGN - SECform4.com Insider Cow View Insider Transactions for NVGN - Insider Cow
CNBC View NVGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for NVGN - OTC Markets
Yahoo View Insider Transactions for NVGN - Yahoo! Finance NASDAQ View Institutional Holdings for NVGN - NASDAQ


Stock Charts

FinViz View NVGN Stock Insight & Charts - FinViz.com StockCharts View NVGN Investment Charts - StockCharts.com
BarChart View NVGN Stock Overview & Charts - BarChart Trading View View NVGN User Generated Charts - Trading View


Latest Financial News for NVGN

Edison Issues ADR Update on Novogen (NVGN)
Posted on Monday September 11, 2017

LONDON, UK / ACCESSWIRE / September 11, 2017 / Novogen (NASDAQ: NVGN) is on track to commence a Phase II trial of GDC-0084 in glioblastoma in Q4 CY17, in line with previous guidance. It plans to meet with ...


Australian cancer specialists may hold key to next advancement in ovarian cancer treatment
Posted on Wednesday August 30, 2017

SYDNEY, Aug. 30, 2017 /PRNewswire/ -- Three leading Australian cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy. Flinders Medical Centre in South Australia and Westmead Hospital in Sydney are also participating, along with leading US hospitals Peggy and Charles Stephenson Cancer Centre, and Mary Crowley Cancer Research Centre. "We've seen massive developments in other types of cancer but ovarian cancer has remained a challenge and, despite it being an unforgiving disease for women, treatment options have fallen behind as money and research are focused elsewhere," Associate Professor Coward said.


GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
Posted on Tuesday August 22, 2017

NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc in October 2016, after completion of a phase I clinical trial in advanced glioma.


Board Review of Business Operations and Governance
Posted on Monday August 14, 2017

NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.


Enter a stock symbol to view the stock details.